Table 1.
General website characteristics.
| Website characteristics | N = 82 | % | |
|---|---|---|---|
| Geographic origin | |||
| USA | 32–82 | 53 | 65.6 |
| UK | 83–109 | 26 | 31.7 |
| Republic of Ireland | 110 | 1 | 1.2 |
| Australia | 111 | 1 | 1.2 |
| Canada | 112 | 1 | 1.2 |
| Funding source | |||
| Private service | 32–35,44,46–49,51,52,54,55,57,60,66–69,71,72,74–77,79,80,89,91,91,92,97–99,104,109,110 | 37 | 45.1 |
| Local NHS trust | 83,88,90,93,94,96,101–104,106,108 | 12 | 14.6 |
| Clinical Website | 36–38,43,53,56,59,64,73,85,100,113 | 11 | 13.4 |
| Wellbeing/lifestyle magazine article | 41,63,73,82,87 | 5 | 6.1 |
| Private blog | 40,58,78,87,111 | 5 | 6.1 |
| Product sales company | 42,86,95,105 | 4 | 4.9 |
| Online encyclopaedia | 50 | 1 | 1.2 |
| Charity | 84 | 1 | 1.2 |
| NTWD condition mentioned | |||
| Osteoarthritis | 32,33,35,42,49–55,61–69,71,72,76,79,84–86,95,98,109,111 | 31 | 37.8 |
| Ganglion | 33,35,42,49–51,53,55,61–63,65–70,80,85,97–100,105,109–111 | 27 | 32.9 |
| Sprain | 43–45,47,48,56,57,63,65,81,88–90,93,94,103,108,110,113 | 19 | 23.2 |
| De Quervain’s | 32,35,37,46,49,50,55,62,64,69,70,76,77,81,97,99,100,110 | 18 | 22 |
| Tendonitis | 42,45,46,50,52,62,63,65,66,71,73,74,76,78,99,109,112 | 17 | 20.7 |
| Ulnar sided | 37,38,50,59,68,76,99,107,109,112 | 10 | 12.2 |
| Strain | 44,47,48,53,67,86,90–92,94 | 10 | 12.2 |
| General wrist pain | 58,59,82,83,96,100–102,106 | 9 | 11 |
| Wrist weakness | 34,36,39–41,87 | 6 | 7.3 |
| Soft tissue injury | 49,50,95,104,107 | 5 | 6.1 |
| DRUJ Tear | 59,99,107,112 | 4 | 4.9 |
| Avascular Necrosis | 35 | 1 | 1.2 |
| Treatment modality recommended | |||
| Splinting | 33,35,37,42,44,44,45,49,50,52–54,54–56,59,60,63–65,67,68,70,73,74,76–79,81–83,85,86,92,94,95,98–102,105,106,108–110,110,112,113 | 51 | 62.2 |
| Ice/cold therapy | 32,35,42–46,49,50,52–54,56,57,59,60,62,63,65,66,73,75–80,82,83,86,88–95,97,99,101–106,110,110,113 | 50 | 61 |
| Non-steroidal anti-inflammatory drugs | 32,35,37,38,43–46,50,52,52–54,54,56,59,62–66,68,70,73,76–79,82–85,88,90,91,93,95–98,100–102,107–110,112,113 | 49 | 59.8 |
| Exercise | 33–43,45,52–54,58,62–65,67,73,75,80,82–88,91,91,93–96,99,101,104,106,109,110,112 | 44 | 53.7 |
| Surgical procedure | 35,37,38,42,47,49,50,52–54,54,59,60,62–68,70,71,73,79,81,85,98,100,102,107,109,112 | 32 | 39 |
| Rest | 32,35,42–46,52–54,56,62,63,73,75–79,83,86,88,92–95,99,101–103,105,110,113 | 31 | 37 |
| Steroid injection | 43,45,46,49,50,53,54,59,60,62–68,76–79,81,100–102,109,112 | 25 | 30.5 |
| Compression | 32,35,50,53,56,57,63,66,67,73,86,90,91,96,97,99,102,104,105 | 19 | 23.2 |
| Activity modification | 42,45,50,59,62,64,65,68,75,77,80,82,83,100–102,107,109,110,112,113 | 21 | 25.6 |
| Physiotherapy | 42,43,49,50,52–54,56,60,64,65,71,74,76,77,90,92,112 | 18 | 22 |
| Elevation | 32,45,46,53,56,57,89–91,96,97,99,102,104,105,108 | 16 | 19.5 |
| Heat | 44,57,64,65,67,77,79–84,101 | 13 | 15.9 |
| Occupational therapy | 46,48–50,52–54,66,71,77,78 | 11 | 13.4 |
| Positional advice | 46,52,54,58,73,75,81,82,101,110,113 | 11 | 13.4 |
| Hand therapy | 32,46,48,67,68,80,98,107,109 | 9 | 11 |
| Manual therapy | 33,48,72,80,82,91,92 | 7 | 8.5 |
| Plasma injection | 45,45,102,109 | 4 | 4.9 |
| Taping | 72,92 | 2 | 2.4 |
| Shockwave | 45,102 | 2 | 2.4 |
| Additional data | |||
| Frequency of treatment detailed | 45,72,74–80,109–111 | 11 | 13.4 |
| Duration of treatment detailed | 33–36,38–41,85–87 | 11 | 13.4 |
| Expected timeframe of recovery | 45,66–72,74–80,83,98,109–111 | 17 | 20.7 |
| Global health markers referred to | 72–76,76–78,80,109–111 | 11 | 13.4 |
| References provided | 33–44,84–92 | 21 | 25.6 |
| Date of last update listed | 36–47,50,62,78,84,86–88,90–97,110,110 | 33 | 40.1 |